• Theranostic Interpolation of Genomic Instability in Breast Cancer.
    • Rasool R, Ullah I, Mubeen B, Alshehri S, Imam SS, Ghoneim MM, Alzarea SI, Al-Abbasi FA, Murtaza BN, Kazmi I, Nadeem MS.
    • Int J Mol Sci. 2022 Feb 7;23(3):1861. doi: 10.3390/ijms23031861.
    • Review
    • Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants?
    • Ivanov M, Sharova M, Olsen A, Lebedeva A, Ignatova E, Mouse G, Mileyko V.
    • J Natl Compr Canc Netw. 2022 Feb;20(2):xxv. doi: 10.6004/jnccn.2021.7103.

    Guideline:

    Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    • Psychiatric symptoms in a Spanish sample with hereditary cancer risk.
    • Costa-Requena G, Garcia-Garijo M, Richart-Aznar P, Segura-Huerta Á,
    • J Community Genet. 2021 Feb 8. doi: 10.1007/s12687-022-00580-5. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Consistency of variant interpretations among bioinformaticians and clinical geneticists in hereditary cancer panels.
    • Agaoglu NB, Unal B, Akgun Dogan O, Kanev MO, Zolfagharian P, Ozemri Sag S, Temel SG, Doganay L.
    • Eur J Hum Genet. 2022 Feb 8. doi: 10.1038/s41431-022-01060-7. Epub ahead of print.
    • Theranostic Interpolation of Genomic Instability in Breast Cancer.
    • Rasool R, Ullah I, Mubeen B, Alshehri S, Imam SS, Ghoneim MM, Alzarea SI, Al-Abbasi FA, Murtaza BN, Kazmi I, Nadeem MS.
    • Int J Mol Sci. 2022 Feb 7;23(3):1861. doi: 10.3390/ijms23031861.
    • Review
    • Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants?
    • Ivanov M, Sharova M, Olsen A, Lebedeva A, Ignatova E, Mouse G, Mileyko V.
    • J Natl Compr Canc Netw. 2022 Feb;20(2):xxv. doi: 10.6004/jnccn.2021.7103.

    Guideline:

    Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  • LitAlert ~~ GeneLit.com

    • Clinical utility of liquid biopsy in breast cancer: A systematic review.
    • Duque G, Manterola C, Otzen T, Arias C, Galindo B, Mora M, Guerrero E, García N.
    • Clin Genet. 2022 Mar;101(3):285-295. doi: 10.1111/cge.14077. Epub 2021 Oct 26.
    • Review
    • Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    • Wagar MK, Mojdehbakhsh RP, Godecker A, Rice LW, Barroilhet L.
    • Gynecol Oncol. 2022 Feb 7:S0090-8258(22)00071-3. doi: 10.1016/j.ygyno.2022.01.032. Epub ahead of print.
    • Theranostic Interpolation of Genomic Instability in Breast Cancer.
    • Rasool R, Ullah I, Mubeen B, Alshehri S, Imam SS, Ghoneim MM, Alzarea SI, Al-Abbasi FA, Murtaza BN, Kazmi I, Nadeem MS.
    • Int J Mol Sci. 2022 Feb 7;23(3):1861. doi: 10.3390/ijms23031861.
    • Review
  • LitAlert ~~ GeneLit.com

    • A Fertility Journey Through the Eyes of a Young Previvor.
    • Walens A.
    • FORCE. Blog. 2022 Feb 8.
    • Psychiatric symptoms in a Spanish sample with hereditary cancer risk.
    • Costa-Requena G, Garcia-Garijo M, Richart-Aznar P, Segura-Huerta Á,
    • J Community Genet. 2021 Feb 8. doi: 10.1007/s12687-022-00580-5. Epub ahead of print.
    • Racial and ethnic enrollment disparities in clinical trials of poly(ADP-ribose) polymerase inhibitors for gynecologic cancers.
    • Wagar MK, Mojdehbakhsh RP, Godecker A, Rice LW, Barroilhet L.
    • Gynecol Oncol. 2022 Feb 7:S0090-8258(22)00071-3. doi: 10.1016/j.ygyno.2022.01.032. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    • Wei G, Teng M, Rosa M, Wang X.
    • Breast Cancer Res. 2022 Feb 8;24(1):11. doi: 10.1186/s13058-022-01507-1.
    • Germline Mutation Analysis in Sporadic Breast Cancer Cases with Clinical Correlations.
    • Ajaz S, Zaidi S, Ali SM, Siddiqa A, Memon MA.
    • Front Genet. 2022 Feb 8;12:820610. doi: 10.3389/fgene.2022.820610.
    • Theranostic Interpolation of Genomic Instability in Breast Cancer.
    • Rasool R, Ullah I, Mubeen B, Alshehri S, Imam SS, Ghoneim MM, Alzarea SI, Al-Abbasi FA, Murtaza BN, Kazmi I, Nadeem MS.
    • Int J Mol Sci. 2022 Feb 7;23(3):1861. doi: 10.3390/ijms23031861.
    • Review
    • Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants?
    • Ivanov M, Sharova M, Olsen A, Lebedeva A, Ignatova E, Mouse G, Mileyko V.
    • J Natl Compr Canc Netw. 2022 Feb;20(2):xxv. doi: 10.6004/jnccn.2021.7103.

    Guideline:

    Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  • LitAlert ~~ GeneLit.com

    • Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    • Wei G, Teng M, Rosa M, Wang X.
    • Breast Cancer Res. 2022 Feb 8;24(1):11. doi: 10.1186/s13058-022-01507-1.
    • Germline Mutation Analysis in Sporadic Breast Cancer Cases with Clinical Correlations.
    • Ajaz S, Zaidi S, Ali SM, Siddiqa A, Memon MA.
    • Front Genet. 2022 Feb 8;12:820610. doi: 10.3389/fgene.2022.820610.
    • Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants?
    • Ivanov M, Sharova M, Olsen A, Lebedeva A, Ignatova E, Mouse G, Mileyko V.
    • J Natl Compr Canc Netw. 2022 Feb;20(2):xxv. doi: 10.6004/jnccn.2021.7103.

    Guideline:

    Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  • LitAlert ~~ GeneLit.com

    • A Fertility Journey Through the Eyes of a Young Previvor.
    • Walens A.
    • FORCE. Blog. 2022 Feb 8.
    • Letter to the Editor: CHEK2 I157T - Pluto Among Numerous Low-Risk Genetic Factors Requiring Discharge From a Range of Pathogenic Variants?
    • Ivanov M, Sharova M, Olsen A, Lebedeva A, Ignatova E, Mouse G, Mileyko V.
    • J Natl Compr Canc Netw. 2022 Feb;20(2):xxv. doi: 10.6004/jnccn.2021.7103.

    Guideline:

    Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.